Ricard Solà

15.8k total citations · 2 hit papers
75 papers, 9.8k citations indexed

About

Ricard Solà is a scholar working on Hepatology, Epidemiology and Surgery. According to data from OpenAlex, Ricard Solà has authored 75 papers receiving a total of 9.8k indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Hepatology, 53 papers in Epidemiology and 13 papers in Surgery. Recurrent topics in Ricard Solà's work include Liver Disease Diagnosis and Treatment (42 papers), Hepatitis C virus research (41 papers) and Liver Disease and Transplantation (20 papers). Ricard Solà is often cited by papers focused on Liver Disease Diagnosis and Treatment (42 papers), Hepatitis C virus research (41 papers) and Liver Disease and Transplantation (20 papers). Ricard Solà collaborates with scholars based in Spain, France and United Kingdom. Ricard Solà's co-authors include Ramón Planas, S. Coll, Richard K. Sterling, Mark Sulkowski, Eduardo Lissen, Nathan Clumeck, Francesca J. Torriani, Diethelm Messinger, David L. Thomas and Doug Dieterich and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Blood.

In The Last Decade

Ricard Solà

74 papers receiving 9.6k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection†‡

2006 3.5k citations Ricard Solà et al. Hepatology profile →
Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

2002 2.7k citations Josep M. Llovet, María Isabel Real et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ricard Solà Spain	31	7.8k	6.7k	1.8k	807	715	75	9.8k
Calogero Cammà Italy	62	7.5k 1.0×	8.4k 1.2×	2.3k 1.3×	1.2k 1.4×	783 1.1×	271	12.0k
Aleksander Krag Denmark	46	6.0k 0.8×	6.3k 0.9×	2.5k 1.4×	917 1.1×	526 0.7×	232	8.7k
Antoine Hadengue Switzerland	52	6.1k 0.8×	5.1k 0.8×	4.0k 2.2×	732 0.9×	903 1.3×	227	9.3k
Yasuji Arase Japan	52	9.1k 1.2×	8.7k 1.3×	726 0.4×	494 0.6×	378 0.5×	394	11.6k
I M Murray-Lyon United Kingdom	27	6.3k 0.8×	5.4k 0.8×	2.2k 1.2×	657 0.8×	653 0.9×	71	9.0k
J Rodés Spain	44	5.1k 0.6×	4.2k 0.6×	2.2k 1.2×	469 0.6×	573 0.8×	187	6.9k
Dominique Thabut France	50	6.2k 0.8×	6.6k 1.0×	2.0k 1.1×	467 0.6×	199 0.3×	207	8.5k
Maurizio Pompili Italy	39	3.2k 0.4×	2.9k 0.4×	1.3k 0.7×	324 0.4×	650 0.9×	231	6.0k
Mario Pirisi Italy	39	2.7k 0.3×	2.8k 0.4×	678 0.4×	754 0.9×	500 0.7×	308	6.1k
Marco Senzolo Italy	48	6.6k 0.8×	5.2k 0.8×	3.0k 1.7×	520 0.6×	411 0.6×	245	8.3k

Countries citing papers authored by Ricard Solà

Since Specialization

Citations

This map shows the geographic impact of Ricard Solà's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ricard Solà with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ricard Solà more than expected).

Fields of papers citing papers by Ricard Solà

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ricard Solà. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ricard Solà. The network helps show where Ricard Solà may publish in the future.

Co-authorship network of co-authors of Ricard Solà

This figure shows the co-authorship network connecting the top 25 collaborators of Ricard Solà. A scholar is included among the top collaborators of Ricard Solà based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ricard Solà. Ricard Solà is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Solà, Ricard, et al.. (2024). 165P From bench to bedside: Functional domains of BRCA mutations for personalized medicine in breast cancer. ESMO Open. 9. 103187–103187.

Garriga, César, Felipe García, Sabela Lens, et al.. (2017). Evolution of acute hepatitis C virus infection in a large European city: Trends and new patterns. PLoS ONE. 12(11). e0187893–e0187893. 6 indexed citations

Sánchez‐González, Blanca, Montserrat Garcı́a-Retortillo, Francesc García‐Pallarols, et al.. (2016). Evaluation of a Hepatitis B Virus Reactivation Prevention Program in Lymphoma Patients Receiving Immunochemotherapy. Blood. 128(22). 1801–1801. 1 indexed citations

Puigvehí, Marc, S. Coll, Montserrat Garcı́a-Retortillo, et al.. (2016). Diagnostic Accuracy of the Enhanced Liver Fibrosis (ELF®) Score Using HCV-Infected Serum Samples Cryopreserved for up to 25 Years. PLoS ONE. 11(12). e0164883–e0164883. 11 indexed citations

Garcı́a-Retortillo, Montserrat, Núria Cañete, S. Coll, et al.. (2014). Drug–drug interactions of telaprevir and boceprevir in HCV ‐monoinfected and HIV / HCV ‐coinfected patients can modify the adherence. Liver International. 35(5). 1557–1565. 5 indexed citations

Udina, Marc, Pere Castellví, J. Moreno-España, et al.. (2012). Interferon-Induced Depression in Chronic Hepatitis C. The Journal of Clinical Psychiatry. 73(8). 1128–1138. 222 indexed citations

Saludes, Verónica, Fernando Gónzález‐Candelas, Ramón Planas, et al.. (2012). Evolutionary dynamics of the E1–E2 viral populations during combination therapy in non-responder patients chronically infected with hepatitis C virus subtype 1b. Infection Genetics and Evolution. 13. 1–10. 4 indexed citations

Díez, Crisanto, Helena Masnou, Ramón Planas, et al.. (2010). Prophylactic Treatment With Escitalopram of Pegylated Interferon Alfa-2a–Induced Depression in Hepatitis C. The Journal of Clinical Psychiatry. 72(4). 522–528. 36 indexed citations

Fernández‐Rodríguez, Conrado, Sonia Alonso Sáenz De Oger, Stella Maris Martínez, et al.. (2010). Peginterferon Plus Ribavirin and Sustained Virological Response in HCV-Related Cirrhosis: Outcomes and Factors Predicting Response. The American Journal of Gastroenterology. 105(10). 2164–2172. 54 indexed citations

10.

Montoliu, Silvia, Belén Ballesté, Ramón Planas, et al.. (2010). Incidence and Prognosis of Different Types of Functional Renal Failure in Cirrhotic Patients With Ascites. Clinical Gastroenterology and Hepatology. 8(7). 616–622. 65 indexed citations

11.

Castellví, Pere, Ricard Navinés, Fernando Gutiérrez, et al.. (2009). Pegylated Interferon and Ribavirin-Induced Depression in Chronic Hepatitis C. The Journal of Clinical Psychiatry. 70(6). 817–828. 23 indexed citations

12.

Romero‐Gómez, Manuel, M. Diago, Raúl J. Andrade, et al.. (2009). Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa‐2a plus ribavirin†‡. Hepatology. 50(6). 1702–1708. 112 indexed citations

13.

Solà, Ricard, Silvia Montoliu, Cristina Tural, et al.. (2006). Poor Response to Hepatitis C Virus (HCV) Therapy in HIV- and HCV-Coinfected Patients Is Not Due to Lower Adherence to Treatment. AIDS Research and Human Retroviruses. 22(5). 393–400. 20 indexed citations

14.

Sánchez–Tapias, José M., M. Diago, P Escartín, et al.. (2006). Peginterferon-Alfa2a Plus Ribavirin for 48 Versus 72 Weeks in Patients With Detectable Hepatitis C Virus RNA at Week 4 of Treatment. Gastroenterology. 131(2). 451–460. 262 indexed citations

15.

Fuster, Daniel, Guadalupe Gómez Melis, Ricard Solà, et al.. (2005). Baseline Factors associated with Haematological Toxicity that Leads to a Dosage Reduction of Pegylated Interferon-α2a and Ribavirin in HIV- and HCV-Coinfected Patients on HCV Antiviral Therapy. Antiviral Therapy. 10(7). 841–847. 17 indexed citations

16.

Solà, Ricard, et al.. (2004). Tacrolimus/mycophenolate mofetil-based immunosuppression in aged kidney transplant. A prospective study. International Immunopharmacology. 5(1). 129–131. 2 indexed citations

17.

Llovet, Josep M., María Isabel Real, Xavier Montañá, et al.. (2002). Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. The Lancet. 359(9319). 1734–1739. 2669 indexed citations breakdown →

18.

Soler, Marta, Mercedes Camacho, Ricard Solà, & Luı́s Vila. (2001). Mesangial cells release untransformed prostaglandin H2 as a major prostanoid. Kidney International. 59(4). 1283–1289. 17 indexed citations

19.

Guilera, M., Xavier Forns, Xavier Torras, et al.. (2000). Pre-treatment with prednisolone does not improve the efficacy of subsequent alpha interferon therapy in chronic hepatitis C. Journal of Hepatology. 33(1). 135–141. 13 indexed citations

20.

Rimola, Antoni, Joan Manuel Salmerón, G. Clemente, et al.. (1995). Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis: Results of a prospective, randomized, multicenter study. Hepatology. 21(3). 674–679. 131 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact